Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan

X
Trial Profile

Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi Pasteur
  • Most Recent Events

    • 09 Mar 2023 Results assessing the immunogenicity and safety of the split-virion inactivated quadrivalent influenza vaccine administered intramuscularly compared with a locally licensed standard-dose influenza vaccine administered subcutaneously in Japan, published in the Vaccine.
    • 15 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 07 Dec 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top